STORM Therapeutics has secured €47.5 million ($56 million) in Series C financing, a follow-on round from existing investors including M Ventures and Pfizer Ventures. This funding will advance their lead candidate, STC-15, a first-in-class METTL3 inhibitor, into a Phase 2 monotherapy study for selected sarcoma indications. The proceeds will also support potential accelerated regulatory approval and further clinical development across additional oncology indications, building on promising Phase 1 results showing durable tumor regression.
Amount: $50.6M
